An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects. Researchers from The University of Texas MD Anderson Cancer Center presented interim findings of the multi-center Phase 2 study at the 54th American Society of Hematology Annual Meeting and Exposition...
HER2-Positive Stem Cells Found In HER2-Negative Breast Cancer
12/20/2012
A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis and treatment of breast cancer...
Prognostic Value Of New IASLC/ATS/ERS Adenocarcinoma Sub-Classification Confirmed By Study
12/20/2012
The International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS), have proposed a new sub-classification of lung adenocarcinomas. A growing number of publications from Australia, Germany and South America have validated the new sub-classification...
Chronic obstructive pulmonary disease (COPD) and lung cancer are two of the most important smoking-related diseases worldwide, with a huge combined mortality bur¬den. Many consider the presence of COPD itself to be an independent risk factor for lung cancer. Others argue that smoking contributes to both COPD and lung cancer...
Immunohistochemistry Found To Be Reliable Screening Tool For ALK Rearrangement
12/20/2012
Favorable results have led to crizotinib gaining approval for the treatment of advanced stage ALK-positive non-small cell lung cancer (NSCLC) in Japan, the United States, Canada, and several other countries in Europe and Asia...
PRT Versus IMRT Toxicity In Medicare Beneficiaries With Prostate Cancer
12/19/2012
There is no difference between proton radiotherapy (PRT) and intensity-modulated radiotherapy (IMRT) when comparing the toxicity among Medicare beneficiary patients with prostate cancer at 12 months post-treatment according to a study published December 14 in the Journal of the National Cancer Institute...
Aranesp Misbranding - Amgen Agrees $762 Million Payment
12/19/2012
After being found guilty of promoting off-label use of Aranesp (darbepoetin alfa), an anemia drug, Amgen Inc. agreed to pay $150 million in criminal fines and penalties. Prosecutors added that the company will also pay $612 in civil settlements. The settlement would include a payment to a former Aranesp product manager, Kassie Westmoreland, to resolve a whistleblower lawsuit...
Colorectal Cancer Screening Guidelines Less Likely To Be Followed By Those Living In Rural Areas
12/19/2012
People who reside in rural areas of Utah are less likely to follow colorectal cancer (CRC) screening recommendations than their urban counterparts, according to researchers from Huntsman Cancer Institute (HCI) at the University of Utah. This geographic disparity is evident across all risk groups, including those who have a family history of the disease...
One In Two Men Will Develop Cancer
12/19/2012
New figures for the UK predict a man's risk of developing cancer during his lifetime will rise to one in two by 2027, largely because more people are living longer...
New Targets For Drugs To Defeat Aggressive Brain Tumor
12/19/2012
University of Pittsburgh Cancer Institute (UPCI) researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line, which could offer new hope for drug treatment to destroy the cancer cells. The results were reported in the cover story of December's issue of the journal Molecular Cancer Research, also available online...